A breakthrough in Alzheimer’s drug development?

As the societal burden of Alzheimer’s disease continues to grow, drug development in the field has struggled to keep up the pace. A huge void in Alzheimer’s therapy remains, however hopes spiked during the fall when Japanese pharma company Eisai presented positive phase III results with anti-Amyloid Beta immunotherapy candidate lecanemab. Since then, however, safety concerns around the drug have emerged after two study participants died from adverse events.

Read the article at biostock.se:

https://www.biostock.se/en/2022/12/a-breakthrough-in-alzheimers-drug-development/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/